Knockdown of DLK4 inhibits non-small cell lung cancer tumor growth by downregulating CKS2

Area of Science:

• Oncology
• Molecular Biology
• Cancer Research

Background:

• Non-small cell lung cancer (NSCLC) is the most common cancer type, accounting for 85% of all lung cancer cases.
• DLX4, a known suppressor of the β-globin gene, has roles in various cancers, but its specific function in NSCLC remains largely unknown.

Purpose of the Study:

• To investigate the expression of DLX4 in human NSCLC cells and tissues.
• To elucidate the role and underlying mechanisms of DLX4 in NSCLC progression.

Main Methods:

• DLX4 expression was analyzed using immunoblot assays and The Cancer Genome Atlas (TCGA) database.
• Cell viability, proliferation, and cell cycle were assessed using CCK-8, colony formation, and flow cytometry (FCM) assays.
• Mechanistic investigations involved immunoblot assays to examine protein expression changes.

Main Results:

• Knockdown of DLX4 significantly inhibited NSCLC cell proliferation and induced cell cycle arrest.
• Downregulation of DLX4 led to suppressed YB-1 expression, which in turn reduced CKS2 expression.
• These molecular changes collectively suppressed NSCLC tumor growth.

Conclusions:

• DLX4 plays a critical role in promoting NSCLC cell proliferation and progression.
• The DLX4/YB-1/CKS2 pathway is implicated in NSCLC development.
• DLX4 inhibition presents a promising therapeutic strategy for NSCLC treatment.